08:00 AM EDT, 10/21/2025 (MT Newswires) -- Neuphoria Therapeutics ( NEUP ) stock was down 67% in recent Tuesday premarket activity after the company said overnight that a phase 3 trial of BNC210 for the acute treatment of social anxiety disorder did not meet its primary endpoint.

Galapagos (GLPG) shares were down 13% after the company said it decided to wind down its cell therapy operations.

Newmont ( NEM ) stock was 4% lower, erasing Monday's gain.

PulteGroup ( PHM ) shares were down 2.1% after the company posted lower Q3 earnings and revenue.